57 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
21 Recruiting GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
Conditions: Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Intervention: Drug: Cyclophosphamide
22 Recruiting Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Condition: Graft Failure
Interventions: Procedure: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors;   Drug: fludarabine;   Procedure: TBI
23 Recruiting Selecting a Favorable KIR Donor in Unrelated HCT for AML
Condition: Acute Myelogenous Leukemia
Interventions: Biological: KIR genotype;   Biological: Unrelated donor transplant
24 Unknown  Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Transplantation;   Procedure: Hematopoietic cell transplantation
25 Recruiting TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Conditions: Primary Immune Deficiency Disorder;   Hematopoietic Stem Cell Transplantation
Intervention: Other: Biological: TCR alfa beta T cell depletion
26 Recruiting Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Condition: Hematologic Neoplasms
Intervention: Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation
27 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex)
28 Recruiting Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Conditions: Leukemia;   Inborn Errors of Metabolism;   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Intervention: Device: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
29 Recruiting Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
Condition: Anemia, Aplastic
Intervention: Drug: Cyclophosphamide,Campath IH and TBI
30 Recruiting Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Conditions: Graft vs Host Disease;   Hematologic Neoplasms;   Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Drug: Vorinostat;   Drug: Tacrolimus;   Drug: Methotrexate
31 Not yet recruiting UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Conditions: Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
32 Unknown  Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
33 Unknown  Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant
Conditions: AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
Intervention: Drug: Abatacept
34 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
35 Unknown  Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Biological: Anti-Thymocyte Globulin (Rabbit);   Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
36 Recruiting Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Condition: Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Clofarabine;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation
37 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
38 Not yet recruiting NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
39 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
40 Recruiting HCT Versus CT in Elderly AML
Condition: Acute Myeloid Leukemia
Interventions: Procedure: hematopoietic cell transplantation;   Drug: Non-Transplant treatment approach for consolidation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-57) Show next page of results    Last Page
Indicates status has not been verified in more than two years